Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
BörsenkürzelTTNP
Name des UnternehmensTitan Pharmaceuticals Inc
IPO-datumJan 18, 1996
CEOMr. Weei Jye Chay
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeJan 18
AddresseSuite 505
StadtSAN FRANCISCO
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl94080
Telefon14152444990
Websitehttps://www.titanpharm.com/
BörsenkürzelTTNP
IPO-datumJan 18, 1996
CEOMr. Weei Jye Chay
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten